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Abstract
Obstructive sleep apnea (OSA), a nightly respiratory condition, is characterized 
by recurrent upper airway collapse causing intermittent hypoxia (IH) resembling 
ischemia and reperfusion (I/R). Consequently, blood oxygenation levels are 
cyclically reduced; sleep fragmentation and sympathetic activation develop, thus 
invoking oxidative stress and inflammation. OSA is a major risk factor for cardio-/
cerebrovascular morbidity and mortality. However, not all OSA patients develop 
cardio-/cerebrovascular disease, even if suffering from similar OSA severity. 
Possibly, this results from interindividual differences in responses to a given 
hypoxic stimulus involving gene polymorphism in oxygen-regulated transcription 
factors and downstream genes. The current review is aimed at highlighting poten-
tially protective mechanisms induced by IH and OSA, rather than its well-estab-
lished deleterious effects, while focusing on acute coronary syndromes. Therefore, 
protective mechanisms revealed in I/R biology and exhibited in vitro and in animal 
models utilizing IH followed by a severe ischemia are discussed and linked to acute 
myocardial infarction patients with concomitant OSA. The roles of endothelial 
progenitor cells, their proliferative and angiogenic properties, and collateral forma-
tion are emphasized in the clinical setting, as well as heterogenic interindividual 
responses to identical hypoxic stimuli. These findings might represent potential 
predictors to cardio-/cerebrovascular health, by identifying patients at higher or 
lower cardiovascular risk.
Keywords: intermittent hypoxia, hypoxia, endothelial progenitor cells (EPCs), 
endothelial cell colony-forming units (EC-CFUs), endothelial tube formation, 
hypoxia-inducible factor (HIF)-1α, vascular endothelial growth factor (VEGF), 
coronary collaterals
1. Introduction
Obstructive sleep apnea (OSA) is a nightly respiratory condition characterized 
by recurrent oropharyngeal upper airway collapse during sleep leading to multiple 
cycles of hypoxic episodes followed by blood reoxygenation. While blocking the 
respiratory system in OSA provokes hypoxic events, resuming respiration induces 
the reoxygenation phase. This intermittent respiration results in multiple cycles of 
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hypoxia and reoxygenation throughout the night which are termed intermittent 
hypoxia (IH). This intermittent respiration directly affects blood oxygenation/
deoxygenation levels altering physiological biochemical and molecular pathways [1].
The significance of OSA to human health stems from its high prevalence 
worldwide, the complaints regarding the quality of life, and the association with 
cardiovascular and other comorbidities. It is identified by a loud and intermittent 
snoring, excessive daytime sleepiness, and polysomnographic respiratory findings. 
In the general population with classical complaints, as loud snoring and excessive 
daytime sleepiness, OSA affects 4 and 2% of adult men and women particularly 
after menopause, respectively. However, these values are much higher in the general 
population not having the classical complaints and are estimated to be as high as 
24% in men and 9% in women. Moreover, in selected populations like the obese and 
the elderly, this value may rise up to 60% [1, 2]. Moreover, OSA is a well-established 
cardiovascular and cerebrovascular risk. It is currently implicated in the etiopatho-
genesis of cardiovascular comorbidities, arrhythmias, congestive heart failure, 
hypertension, atherosclerosis, and stroke [1].
Intermittent hypoxia is in fact the hallmark of OSA. Consequently, many physi-
ological, cellular, and biochemical alternations occur due to the cyclically reduced 
blood oxygenation levels, sleep becomes fragmented, and sympathetic nerve activ-
ity develops [3]. The severity of the IH and the hypoxemia in OSA are determined 
by the number of the hypoxic events per hour of sleep, termed Apnea-Hypopnea 
Index (AHI). It mostly ranges from a cutoff point of 10 events per hour of sleep for 
normal breathing to mild (11–20), moderate (21–30), and severe OSA (>30 events 
per hour of sleep). In severe patients, blood oxygenation levels can intermittently 
drop to as low as 60%.
Events of IH in OSA and in animal models treated with IH were shown to elicit 
cell and tissue injury by increasing the formation of reactive oxygen species (ROS) 
and promoting inflammatory pathways. Both oxidative stress and inflammation are 
fundamental mechanisms in various pathologies, inducing vascular dysfunction, tran-
scriptional reprograming, inflammation, and innate and adaptive immune activation, 
all of which are contributors of morbidity and mortality in a vast array of cardiovas-
cular and other morbidities [4]. This sequence of events initiated by IH is illustrated in 
Figure 1, which was adapted from Lavie [3] and published by Levy et al. [1].
To date, the deleterious effects of OSA and IH on the cardio-/cerebrovascular 
system are well established, many of which result from the IH-associated oxidative 
stress, systemic inflammation, and sympathetic nerve activation. These fundamental 
components are largely responsible for inducing endothelial dysfunction and vascular 
comorbidities in these patients [1, 3]. Specifically, IH was shown to induce activation 
of various leukocyte subpopulations, by increasing their ROS and inflammatory cyto-
kine production. Moreover, increased expression of adhesion molecules, increased 
avidly of OSA monocytes to endothelial cells, inhibition of neutrophil apoptosis, and 
increased cytotoxicity of CD8+ T lymphocytes and γδ T cells toward endothelial cells 
were also shown to contribute to endothelial cell damage, as illustrated in Figure 1 
[3, 5–7]. Thus, the multiple cycles of IH in OSA have been shown to resemble mecha-
nisms of ischemia and reperfusion (I/R) injury by eliciting similar fundamental 
mechanisms, including increased ROS production, activated leukocytes, inflamma-
tion, transcriptional reprograming, and vascular dysfunction [5, 6, 8].
Importantly, although the most prominent and notable effects of I/R reveal tis-
sue and organ injury leading to cardiovascular and cerebrovascular morbidity, I/R 
was also shown to confer cardioprotection by activating adaptive mechanisms such 
as ischemic preconditioning (IPC), post-conditioning, and remote-conditioning 
[9]. Thus, since not all OSA patients develop cardiovascular and other morbidi-
ties, it is feasible that in some instances IPC may occur in OSA as well. Apparently, 
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genetic polymorphism in HIF-1 and downstream genes as vascular endothelial 
growth factor (VEGF) and erythropoietin (EPO) might influence the individual 
responses to a given IH stimulus. However, also environmental- and lifestyle-related 
variables (diet, sports, air pollution) could affect these individual responses [1, 3].
Figure 1. 
Oxidative stress promotes sympathetic activation, cellular and systemic inflammation, and vascular 
comorbidities in OSA. Intermittent hypoxia induces the production of reactive oxygen species (ROS), 
resulting in oxidative stress by inducing mitochondrial dysfunction, activating NADPH oxidase (NOX) and 
xanthine oxidase (XOX), and inducing nitric oxide synthase (NOS) uncoupling. Interaction of ROS with 
nitric oxide (NO) further promotes oxidative stress while diminishing the bioavailability of NO and thus 
promoting hypertension, inflammation, endothelial dysfunction, hypercoagulability, and atherosclerosis. The 
ROS-dependent increase in sympathetic activation and in angiotensin II and endothelin 1 levels contribute 
to hypertension. Concomitantly, ROS can upregulate numerous redox-sensitive transcription factors, such as 
nuclear factor-κB (NF-κB), hypoxia-inducible factor-1α (HIF-1α), and nuclear factor (erythroid-derived 
2)-like 2 (NF2L2). NF-κB orchestrates the various inflammatory processes that lead to endothelial dysfunction 
and atherosclerosis. By contrast, HIF-1α and NF2L2, which are also upregulated by ROS levels, are involved in 
protective mechanisms, which may counteract some of deleterious effects of ROS. Comorbidities and conditions 
associated with OSA, such as hypercholesterolemia, diabetes mellitus, and obesity, also have a ROS component 
and involve NF-κB activation and inflammation. Broken line, indirect pathway; red line, inhibition. Figure 
adapted from Ref. [3], Elsevier and published in Lévy et al. [1].
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The current review is aimed at highlighting potentially protective mechanisms 
induced by IH and OSA rather than the deleterious and well-established injurious 
effects described above while focusing on OSA patients with concomitant acute 
coronary syndromes. Thus, protective mechanisms revealed in I/R biology and also 
exhibited in animal models of IH after a global ischemic insult, as well as in patients 
with acute myocardial infarction (AMI) and concomitant OSA, are discussed and 
further elaborated in models of IH in vitro. A special emphasis is put on endothelial 
progenitor cells (EPCs), their proliferative and angiogenic properties, and their 
association with collateral formation. The significance of the heterogeneity in the 
proliferative and angiogenic functions of EPCs from healthy individuals exposed to 
a given identical IH stimulus is discussed with regard to potential collateral develop-
ment and cardiovascular outcomes. Understanding individual differences to various 
forms of hypoxia and the associated molecular pathways can help in identifying 
patients at higher or lower cardiovascular risk.
2. Protective mechanisms associated with ischemia and reperfusion
The preconditioning effect is basically an experimental strategy. Applying brief 
ischemic episodes each followed by reperfusion—prior to a longer and potentially 
lethal duration of ischemia—can confer protection to an organ or a tissue. IPC of 
the heart is the best studied one. It demonstrates the heart’s own self-preserving 
mechanism, by reducing infarct size and ventricular arrhythmias, and was shown in 
many of the models studied. In the first and seminal study demonstrating IPC [10], 
dog hearts were preconditioned by undergoing four circumflex coronary occlusions 
each lasting 5 min, separated each by 5 min of reperfusion (a total of 40 min), fol-
lowed by a sustained 40 min occlusion and 4 days of reperfusion recovery. Control 
animals underwent only a single 40 min of occlusion and 4 days of reperfusion 
recovery after which infarct size was measured. In the controls, the infarcted area 
consisted 30% of the area at risk, whereas that of the preconditioned animals was 
only 7.5% of the area at risk (25% of the infarct size in the controls). This landmark 
study has paved the way to subsequent studies demonstrating the protective effects 
of IPC in the kidney, brain, liver, and intestine [11, 12]. Moreover, in various stud-
ies, the paradigms of IPC varied considerably ranging from intervals of minutes to 
seconds. Thus, when nonlethal sequential episodes of I/R—like those occurring in 
OSA nightly, prior to the occurrence of an acute lethal I/R episode—like in AMI or 
stroke, preconditioning may occur in those patients.
2.1  Mechanisms of ischemic preconditioning in animal models of intermittent 
hypoxia
The mechanisms involving IPC are complex and intricate, implicating various 
molecular, cellular, and paracrine pathways. Some of the triggers, mediators, and 
targets activated by I/R include Ca+2 ions, ROS, reactive nitrogen species, purinergic 
signaling, kinases, cytokines, and mitochondria. Transcriptional reprograming is 
affected as well. It involves upregulation of the redox-sensitive transcription factor 
hypoxia-inducible factor (HIF)-1α and its downstream genes VEGF and EPO and 
inducible nitric oxide synthase (iNOS) [4, 12]. The angiogenic VEGF promotes 
neovascularization and collateral vessel formation, while EPO is essential for 
protection against I/R injury. Nuclear factor kB (NF-κB) and some of its regulated 
inflammatory pathways are activated as well. Collectively, these transcriptional 
alterations invoke cellular and paracrine functions. In that context, a number of 
studies utilizing animal models of IH were shown to reduce infarct size in rat hearts 
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and improve focal ischemic injury in mice. In an acute model of IH, isolated rat 
myocardium was exposed to 4 h or 30 min of preconditioning by IH, using hypoxic  
episodes of either 10 or 5% oxygen, lasting 40 s and normoxia at 21% O2 for 20 s  
(60 IH events per hour). After 24 h of recovery, sustained ischemia lasting 30 min was 
followed by 120 min of reperfusion. Only the paradigm of 4 h of IH at 10% oxygen 
induced a delayed preconditioning by reducing infarct size to more than 50% 
as compared to control hearts [13]. Moreover, besides reducing infarct size, also 
HIF-1α was stabilized and iNOS was activated. These effects were mediated through 
PKC and triggered by P38 MAPK and ERK1/ERK2 while inhibiting iNOS with 
aminoguanidine before the ischemic period abolished the IPC phenomenon [14]. 
In a chronic IH model investigating focal ischemic injury in mice, a dichotomous 
effect was noted. The mice were subjected to chronic IH at 10 or 6% O2 for 35 days 
(8 h/day 20 hypoxic episodes/hour lasting 90 s at 90 s of intervals) or to room air 
(sham). Then the mice were treated for focal ischemic injury for 30–35 min. Only 
at 10% of O2, EPO and VEGF were increased, while inflammatory markers were 
decreased compared to controls. At the more severe IH of 6% of O2, inflammatory 
markers were increased as compared to control sham animals [15]. In both the acute 
and the chronic IH animal models described, the IH served as a nonlethal precon-
ditioning effect before applying the lethal I/R stimulus. Acute as well as chronic 
IH displayed dichotomous effects, depending on the severity of the IH applied. 
Moreover, the molecular mechanisms described for IH-dependent IPC concur with 
classical IPC mechanisms in I/R (upregulation of HIF-1α, VEGF, EPO, and iNOS). 
Thus, the protective effects were dependent on the severity, the frequency, and the 
chronicity of the IH paradigms applied in these animal models of IH.
2.2  Potential involvement of IPC in OSA patients with acute MI and acute 
ischemic stroke
The involvement of IPC is potentially implicated in patients with OSA after an 
AMI or an acute ischemic stroke. For instance, peak cardiac troponin values were 
shown to be significantly higher in AMI patients without OSA than in AMI patients 
with OSA. This finding suggests that OSA might have a protective effect in the 
context of MI and that patients with OSA may experience less severe myocardial 
injury [16]. Additionally, the prevalence of non-ST-elevation myocardial infarction 
(NSTEMI) in AMI patients was associated with OSA and was shown to increase with 
the increasing severity of OSA. This finding may also suggest a cardioprotective role 
of OSA, which may attenuate the development of ST-elevation myocardial infarction 
(STEMI), perhaps through IPC [17]. In patients with OSA hospitalized because of an 
acute ischemic stroke, less severe neurological injury and lower unadjusted mortality 
rates were found than in those without a history of OSA [18]. Also, cardiac arrest sur-
vivors with OSA had better unadjusted survival rates and favorable adjusted neuro-
logical outcomes at discharge than those without OSA [19]. This latter study suggests 
that OSA patients may tolerate better acute brain ischemia due to preconditioning. 
Collectively, these recent studies favor the possibility that the presence of OSA may 
confer cardio-/neuroprotection in patients with AMI or acute ischemic stroke.
3. The role of endothelial progenitor cells in endothelial health
Blood-derived EPCs play a pivotal role in maintaining vascular homeostasis by 
providing an endogenous repair mechanism by replacing dysfunctional endothelium 
and enhancing tissue repair after an ischemic vascular insult [20, 21]. EPCs are mobi-
lized by hypoxia or tissue ischemia, HIF-1α- and VEGF-dependent pathways [22]. 
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In AMI patients, EPCs were shown to home at the ischemic myocardium and 
 participate in vascular and cardiac repair, basically acting as an internal pool of 
endothelial cells (ECs). EPCs contribute up to 25% of ECs in newly developed 
vessels at ischemic sites. Hence, they promote coronary collateral formation while 
improving endothelial functions by integrating into newly developing capillaries 
or into injured blood vessels [20, 23]. Of note, low EPC numbers were shown to 
correlate with endothelial dysfunction, atherosclerosis, and poor cardiovascular 
outcome. Thus, they are currently considered in many studies to represent an inde-
pendent predictor of endothelial dysfunction and long-term prognosis in patients 
with coronary artery disease [21, 24]. Therefore, circulating EPC levels might be 
used as a surrogate marker to assess clinical outcomes.
In most of the studies published thus far, EPCs were primarily identified by 
CD34 (primitive hematopoietic progenitors) and VEGF-R2 (a VEGF receptor) 
expressions [20]. Their proliferative and angiogenic capacities were demonstrated 
in vitro by two widely used assays: (1) the formation of endothelial colonies in 
culture—termed endothelial cell colony-forming units (EC-CFUs) [25]—and (2) 
the determination of the paracrine effects of these developed colonies on endothe-
lial cells in culture [26].
Growing EPCs on fibronectin in vitro can induce proliferation and differentia-
tion into EC-CFUs which are characterized by a central core of round angiogenic 
T cells and outgrowing spindle-shaped cells. These colonies secret angiogenic growth 
factors such as VEGF inducing endothelial tube formation via paracrine pathways. 
Moreover, in AMI patients the expression of circulating EPCs (CD34+/VEGF-R2) 
was positively correlated with mean endothelial tube formation [27]. Also, EC-CFUs 
were shown to negatively correlate with the Framingham risk score, thus adequately 
representing circulating EPCs [25]. Both these two in vitro measures—the formation 
of EC-CFUs in culture and their paracrine effects on endothelial tube formation—
might be considered as good surrogate markers for circulating EPCs [25, 27].
3.1  Endothelial progenitor cells and their proliferative and angiogenic 
properties in AMI patients with OSA
Acute MI can be a devastating I/R event and a frequent cause of sudden death. 
Sleep apnea is highly prevalent in AMI patients, ranging in various studies from 
22 to 69%. However, in the setting of AMI, the presence of OSA is frequently not 
considered and therefore under diagnosed [28]. Evaluating circulating EPCs in 
patients diagnosed with OSA while recovering from an AMI revealed significantly 
higher EPC numbers than in AMI patients without OSA. Also the intracellular 
VEGF expression, EC-CFU numbers, and their angiogenic T cells in culture, and 
endothelial tube formation, were all significantly higher than those in AMI patients 
without OSA [27]. These findings suggest that the IH associated with OSA might 
have a crucial role in promoting these protective functions of EPCs in the setting of 
AMI. Subsequently, the development of EC-CFUs and their paracrine functions in 
healthy individuals were determined by exposure to IH in vitro. Indeed, the pro-
liferative and paracrine abilities of EC-CFUs and endothelial tube formation were 
increased by IH, as compared to those that developed under normoxic conditions 
[27, 29]. Moreover, IH in vitro increased NADPH oxidase-dependent ROS produc-
tion, protein carbonylation, and VEGF expression in EC-CFUs. Both EC-CFU num-
bers and endothelial tube formation in culture were increased by ROS-dependent 
mechanisms. Accordingly, ROS scavengers and NADPH oxidase inhibitors attenu-
ated or completely abolished the formation of EC-CFUs treated by IH in vitro. It is 
therefore likely that IH and ROS are crucial contributors to increased EPC numbers 
and their proliferative and angiogenic functions [29].
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4. Development of coronary collaterals in acute coronary syndromes
A number of studies demonstrate that coronary collaterals were increased in 
coronary artery disease patients with high EPC numbers. Conversely, inadequate 
coronary collateral development was associated with reduced numbers of circulat-
ing EPCs and impaired pro-angiogenic activity, as determined by the low values of 
EC-CFUs and tube formation in culture [30, 31]. Moreover, increased circulating 
EPC levels were also associated with collateral formation in patients with NSTEMI 
[32]. Furthermore, reduced circulating EPC numbers also predicted future cardio-
vascular events, emphasizing the clinical importance of endogenous vascular repair 
[30, 31, 33]. Therefore, circulating EPC numbers might represent a good prognostic 
marker for the outcomes in the clinical context of acute coronary syndrome [20].
Interestingly in OSA patients with total coronary occlusion, collateral develop-
ment was significantly higher than in non-OSA patients with the same coronary 
occlusion (Rentrop score 2.4 ± 0.7 vs. 1.61 ± 1.2, p = 0.02, respectively) [34]. Similar 
finding supporting increased coronary collaterals in inaugural AMI patients with 
OSA was also reported more recently [35].
5. Interindividual responses to hypoxic conditions
Interindividual differences are fundamental to the development of personal-
ized medicine. Different individuals respond in a distinctively different manner 
to an identical hypoxic stimulus. Such diverse responses can result from a number 
of reasons. Specifically, however, genetic variations in the expression of oxygen-
regulated genes are of a particular interest in this growing field of personalized and 
regenerative medicine, as EPCs and their proliferative and angiogenic functions are 
[3]. For instance, the expression of the transcription factor HIF-1α and some of its 
downstream genes as VEGF and aldolase C was determined in lymphocytes from 
healthy adults exposed to eight different hypoxic treatments ranging from 0.1 to 20% 
oxygen. The sensitivity of HIF-1α expression to hypoxia varied considerably between 
individuals. HIF expression in the “low responders” was upregulated at 0.1% oxygen, 
whereas “high responders” upregulated HIF already at 5% oxygen. Moreover, also the 
HIF-regulated downstream genes responded in the same manner in each individual, 
suggesting that the source of this variation resides within the HIF system itself [36]. 
Furthermore, in patients with ischemic heart disease, DNA was genotyped for single-
nucleotide polymorphism (C or T changes at residue 582 of HIF-1α, from proline to 
serine). HIF-1α polymorphism was associated with the development of collaterals in 
those patients and was dependent on the frequency of the T alleles. Its frequency was 
higher in patients without collaterals than in patients with collaterals (the presence 
of CT or TT was a negative predictor). Thus, variations in HIF-1α genotype may 
influence the development of collaterals in patients with significant coronary artery 
disease perhaps regardless of the severity of the ischemia they encounter [37]. In 
an earlier study, interindividual responses to hypoxia were also shown in coronary 
artery disease patients undergoing angiography. Their monocytes were harvested 
and exposed to an identical hypoxic stimulus. Then, mRNA levels of VEGF were 
determined and correlated with the presence of collaterals. Patients with no collater-
als had significantly lower hypoxic induction of mRNA VEGF levels, whereas high 
mRNA VEGF levels were correlated with high collateral formation [38]. Collectively, 
these latter studies emphasize the heterogenic responses observed between differ-
ent individuals exposed to an identical hypoxic stimulus, due to a different genetic 
background. Moreover, the significance of collateral development in the context of 
individual responses and clinical outcomes is further emphasized.
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Since high levels of EC-CFUs and endothelial tube formation were correlated 
with high collateral formation [30, 31], we investigated the effects on EC-CFUs, 
endothelial tube formation, and VEGF levels in young healthy adults by apply-
ing IH in vitro. As aforementioned, IH increased the formation of EC-CFUs and 
their paracrine activity by increasing endothelial tube formation via higher VEGF 
expression in culture [29]. However, there was also a significant variation within 
the cellular responses to the hypoxic stimuli between individuals as depicted in 
Figure 2. This latter finding emphasizes again the importance of the interindividual 
heterogeneity observed in the hypoxic responses to a specific stimulus as described 
earlier for the HIF system and the downstream genes in cardiovascular patients as 
well as in healthy individuals [36–38].
6. Conclusions
Intermittent hypoxia is the hallmark of obstructive sleep apnea. However, 
many of the molecular pathways activated in OSA and in response to IH in vivo 
and in vitro resemble pathways activated by ischemia and reperfusion (I/R). This 
is evident in injurious as well as in protective mechanisms. IH, similar to I/R, 
promotes fundamentally injurious mechanisms as oxidative stress and inflam-
mation which invoke atherosclerotic processes rendering OSA a major risk factor 
for cardio- and cerebrovascular disease. Yet, not all OSA patients develop these 
morbidities. Importantly, also, similar to I/R, some OSA patients with concomitant 
acute MI respond to the harsh effects of IH by activating akin molecular pathways 
Figure 2. 
Individual and mean EC-CFU numbers were determined on the 7th day in culture in 15 healthy donors. 
Cells were exposed to intermittent hypoxia (IH) and to sustained hypoxia (SH) and compared to normoxia 
(Norm). Each symbol represents a different donor. The horizontal black bar represents the average value for 
each treatment. (IH 12.7 ± 10.0 vs. Norm 5.0 ± 3.3 EC-CFUs/well, p < 0.017; SH 5.4 ± 4.7 vs. Norm EC-CFUs/
well, p = NS). These data were published in Avezov et al. [29].
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which promote protective mechanisms as ischemic preconditioning. It is therefore 
likely that OSA promotes IPC in some instances as well. This is particularly evident 
in patients recovering from AMI.
Both IH and ROS were shown to play a major role in increasing EPC and 
EC-CFU numbers and angiogenic functions. All in all, circulating EPC numbers 
and their angiogenic functions were shown to represent a good surrogate marker as 
well as a prognostic marker to assess the outcomes in the clinical context of acute 
MI. This is emphasized by their association and significance to collateral develop-
ment and clinical outcome. Moreover, the heterogenic responses observed between 
individuals, implicating a specific personal response to a given particular stimulus, 
based on genetic variants, might be considered as the foundation for developing 
personalized medicine for acute MI patients. Thus, IH might be considered as a new 
modality for the upregulation of angiogenic processes to induce collateral formation 
in the clinical setting. However, the severity, the frequency, and the chronicity of 
the IH paradigms should be determined in order to identify and harness IH patterns 
possessing protective effects. Collectively, based on the studies presented in this 
review, it is clearly evident that determination of collateral formation, EPC num-
bers (and possibly their proliferative and angiogenic properties), HIF polymor-
phism, downstream genes as VEGF, and additional markers, yet to be unraveled, 
represent an important tool to identify patients at higher or lower risk for outcomes 
of acute coronary syndromes. However, no less important is the identification of IH 
patterns possessing protective effects toward elevating EPC numbers in the circula-
tion of acute MI patients with low or unfavorable HIF polymorphism.
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